Key Highlights
- Fresh post hoc analyses on Wegovy (semaglutide) were unveiled at the ADA 2026 Scientific Sessions, examining impacts on sleep apnea, asthma, cardiovascular health, and hepatic function.
- Amycretin’s phase 2 trial demonstrated weight reductions reaching 14.6% alongside a 1.71 percentage point decrease in A1C levels across 36 weeks.
- As a dual GLP-1 and amylin receptor agonist in a single molecule, amycretin is advancing toward phase 3 development.
- Over the last 24 months, NVO stock has plummeted approximately 68% amid intensifying competition and clinical setbacks.
- The oral formulation of Wegovy continues drawing patients, while experimental candidates like UBT251 broaden the company’s therapeutic arsenal.
Novo Nordisk has witnessed its stock price collapse by roughly 68% during the previous two years. For a pharmaceutical giant that once dominated the obesity treatment landscape, this represents a dramatic reversal of fortune. Yet beneath the surface, several noteworthy developments are unfolding.
During the American Diabetes Association’s 2026 Scientific Sessions, the Danish pharmaceutical company unveiled multiple retrospective analyses derived from its SELECT, STEP, ESSENCE, and OASIS clinical programs. These evaluations examined how semaglutide — the mechanism behind both Wegovy and Ozempic — influences health conditions extending beyond simple weight management.
One retrospective evaluation revealed that semaglutide injection at 2.4 mg dosing correlated with a 52% reduction in obstructive sleep apnea incidence versus control groups, achieving a hazard ratio of 0.48. Among study participants without baseline OSA diagnoses, researchers documented 30 incident cases in the semaglutide cohort compared to 65 among placebo recipients.
A separate analysis examined asthma outcomes. Subjects with confirmed cardiovascular disease, concurrent asthma, and obesity receiving semaglutide experienced fewer asthma-associated adverse events — 27 incidents versus 46 in the control arm, yielding a hazard ratio of 0.58. The treatment also produced a 38.9% decrease in hsCRP, an important inflammatory biomarker.
Regarding cardiovascular parameters, a combined analysis of STEP program data determined that semaglutide lowered systolic blood pressure by an estimated 5.48 mmHg beyond placebo effects in subjects with inadequately controlled hypertension. Diastolic measurements declined by 2.73 mmHg.
Hepatic health findings from the ESSENCE program demonstrated sustained improvements in cardiometabolic risk indicators and liver biomarkers through week 72, independent of participants’ initial glycemic status.
Amycretin Phase 2 Results Generate Momentum
The more significant development centers on amycretin. Novo Nordisk disclosed phase 2 findings indicating this compound — a unified dual GLP-1 and amylin receptor agonist molecule — achieved weight reductions up to 14.6% alongside a 1.71 percentage point A1C decline from a 7.8% starting point during 36 weeks of treatment. Control group participants experienced merely 2.1% weight reduction.
Importantly, higher dosage levels revealed no apparent weight loss plateau. This dose-responsive characteristic represents precisely what both investors and clinical researchers hope to observe as the program transitions into phase 3 evaluation.
Unlike CagriSema, which merges two distinct molecular entities, amycretin functions as a single integrated molecule. This design could translate to enhanced effectiveness and streamlined production processes. The company intends to pursue development of both injectable and oral delivery formats.
Factors Behind the Stock Decline
The previous 24 months have presented significant challenges. Eli Lilly’s Zepbound demonstrated superior weight reduction outcomes in head-to-head clinical evaluations, while CagriSema underperformed against management’s projected 25% mean weight loss benchmark. The compound also failed in direct comparison trials versus Zepbound.
Financial performance has suffered accordingly. Novo Nordisk reduced its outlook repeatedly throughout 2025 and presently anticipates revenue contraction for the 2026 fiscal period.
The oral Wegovy formulation has emerged as a positive development, attracting patients previously hesitant about injectable therapies. Pipeline asset UBT251, a triple gut hormone agonist, has generated encouraging phase 2 outcomes in Chinese markets.
Detailed phase 3 protocol specifications for amycretin and any comparative efficacy data against rival GLP-1 therapeutics will constitute the critical upcoming milestones for market observers.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
